Title
Category
Credits
Event date
Cost
Advances in Non-Steroidal Topicals: PDE-4 Inhibitors for Seborrheic Dermatitis and Beyond
  • 0.75 AMA P...See more
  • 0.75 ANCC
$0.00
Traditional treatments for seborrheic dermatitis, including oral and topical steroids, present a variety of challenges including lack of efficacy, adverse events with long-term use, limitations for adherence, and the inability to treat both hair- and non-hair-bearing areas. Recently, the first targeted therapy for treatment of seborrheic dermatitis, a PDE-4 inhibitor topical foam, was approved by the FDA.
A New Wave of Topical Therapies for Atopic Dermatitis: Comparing Treatment Approaches
  • 1.00 AANPSee more
  • 1.00 AAPA Category I CME
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
$0.00
Topical therapies are considered the mainstay treatment for atopic dermatitis (AD). However, traditional topicals such as corticosteroids and calcineurin inhibitors are associated with limitations for use and safety concerns. In addition, treatment guidelines for AD provide few to no recommendations for selecting therapies and, as a result, treatment selection for each patient can be complex and subjective. New targeted topical therapies are becoming increasingly available, and clinicians must be familiar with the latest clinical data and how to utilize them in clinical practice.
Psoriasis in Skin of Color Unplugged: Addressing the Barriers to Patient Care and Relief
  • 1.00 AMA P...See more
  • 1.00 ANCC
$0.00
Various gaps in the management of psoriasis patients with skin of color (SOC) persist due to a lack of training on SOC and inherent barriers to care. As a result, psoriasis patients with SOC are often misdiagnosed, experience more severe disease, and experience more disease burden. Recent clinical trial data supports the need for nuanced care when treating psoriasis patients with SOC using systemic agents. It is important that clinicians are able to identify treatment barriers and develop strategies to address these barriers and personalize care.
Scratching the Surface of BTK Inhibition for Chronic Spontaneous Urticaria: Beyond Skin Deep
  • 1.00 AMA P...See more
  • 1.00 ANCC
$0.00
BTK inhibitors have demonstrated great promise for addressing various treatment challenges for chronic urticaria patients by improving symptom control and more effective targeting of disease pathways.
Addressing Unmet Needs and Disease Burden in Chronic Spontaneous Urticaria: A Clinical Escape Room Challenge
  • 0.50 AMA P...See more
  • 0.50 ANCC
$0.00
Chronic spontaneous urticaria (CSU) has unpredictable symptoms without an obvious external cause; however, the symptoms of CSU, such as hives, itching and swelling, mimic an allergic reaction, and there is often significant time spent finding an external trigger. Despite current treatment options for CSU, treatment resistance and poor symptom control remain significant challenges; only 40% of patients achieve complete symptom control with standard therapy.
Trading Steroids for Targeted Topical Therapies: Clinical Pearls for Your AD, Psoriasis, and Seborrheic Dermatitis Patients
  • 0.50 AAPA ...See more
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 ANCC
$0.00
While corticosteroids hold a valuable place in the therapeutic toolkit for atopic dermatitis, psoriasis, seborrheic dermatitis, and similar conditions, targeted topical therapies may offer better options for individualized care. Non-steroidal targeted therapies allow for better efficacy, improved safety, long-term use, and treatment of sensitive regions of the skin. Health care professionals require expert guidance on clinical data for new and emerging targeted topical therapies and strategies for utilizing them to improve outcomes in adult and pediatric patients.
JAK is Out of the Box: Leveling Up Care for Severe Alopecia Areata Across Patient Populations
  • 0.75 AAPA ...See more
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC
$0.00
Severe alopecia areata (AA) causes a significant disease burden impacting multiple aspects of patients’ health, quality of life, and daily functioning. New treatment options, including Janus kinase (JAK) inhibitors, are becoming available, but diagnosis and management can be challenging, especially for pediatric patients and those with skin of color.